Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies

Summary

Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts: 1. Cohort 1: The "captive" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density. 2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years. Demographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database. The primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.

Eligibility

Study population cohort 1

* Inclusion Criteria

  * Adult patients (≥18 years old) affiliated to the health plan of Hospital Italiano de Buenos Aires.
  * Documented clinical follow-up of at least 1 year during the study period.
* Exclusion Criteria

  * Patients not affiliated to the health plan of the Hospital Italiano de Buenos Aires.

Study population cohort 2

* Inclusion Criteria

  * Adult patients (≥18 years) with histopathologically confirmed diagnosis of low-grade glioma (WHO grades I and II).
* Exclusion Criteria

  * Incomplete or doubtful diagnosis based on histopathologic and molecular criteria.

Conditions2

Browse More Trials